aTyr Pharma stock holds Buy rating as Phase 3 trial completes

Published 23/07/2025, 12:34
aTyr Pharma stock holds Buy rating as Phase 3 trial completes

Investing.com - H.C. Wainwright has reiterated its Buy rating and $35.00 price target on aTyr Pharma (NASDAQ:ATYR) after the company announced the completion of its pivotal Phase 3 EFZO-FIT study. The stock, which has gained over 47% in the past six months despite a recent 10% weekly decline, currently trades at $5.24. According to InvestingPro data, three analysts have revised their earnings upwards for the upcoming period.

On July 22, aTyr Pharma reported that the last patient has completed their final visit in the Phase 3 trial of efzofitimod, the company’s lead therapeutic candidate for pulmonary sarcoidosis, a major form of interstitial lung disease.

The global, randomized, double-blind, placebo-controlled study enrolled 268 patients and was designed to last 52 weeks, with participants randomized equally to receive either 3.0 mg/kg or 5.0 mg/kg intravenous doses of efzofitimod, or placebo, once monthly for a total of 12 doses.

The primary endpoint of the EFZO-FIT study is steroid reduction, with secondary endpoints including measures of lung function and sarcoidosis symptoms, incorporating a forced steroid taper protocol throughout the trial period.

aTyr Pharma is expected to report topline data from the EFZO-FIT study later this quarter, with H.C. Wainwright noting that the trial represents the first-ever global Phase 3 study for patients with sarcoidosis and could potentially address significant clinical demand where conventional treatments are limited or associated with high toxicity risks. With analyst targets ranging from $9 to $35, investors can access detailed financial analysis and 12 additional ProTips through InvestingPro’s comprehensive research reports.

In other recent news, aTyr Pharma has reported positive interim results from its Phase 2 study of efzofitimod for treating systemic sclerosis-related interstitial lung disease (SSc-ILD). The study highlighted clinically significant improvements in patients, with three out of four participants showing notable progress. Additionally, aTyr Pharma is set to be included in the Russell 2000 and Russell 3000 indexes, effective June 27, 2025, marking its recognition among the largest publicly traded U.S. companies. H.C. Wainwright analysts have reaffirmed a Buy rating on aTyr Pharma, maintaining a $35 price target following interim findings from the EFZO-CONNECT study. Leerink Partners also continues to rate aTyr Pharma as Outperform, expressing optimism about the upcoming Phase 3 EFZO-FIT readout for efzofitimod in pulmonary sarcoidosis. Furthermore, aTyr Pharma is advancing its investigational drug candidate, ATYR0101, which will be highlighted at the American Thoracic Society 2025 Respiratory Innovation Summit. The candidate has shown promise in preclinical models for its unique anti-fibrotic properties. These developments reflect aTyr Pharma’s ongoing efforts in advancing its therapeutic pipeline.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.